ChemicalBook CAS DataBase List (2b,3a,5a,16b,17b)-17-Acetoxy-3-hydroxy-2-(4-morpholinyl)-16-(1-pyrrolidinyl)androstane

(2b,3a,5a,16b,17b)-17-Acetoxy-3-hydroxy-2-(4-morpholinyl)-16-(1-pyrrolidinyl)androstane synthesis

8synthesis methods

Product Name:(2b,3a,5a,16b,17b)-17-Acetoxy-3-hydroxy-2-(4-morpholinyl)-16-(1-pyrrolidinyl)androstane
CAS Number:119302-24-8
Molecular formula:C29H48N2O4
Molecular Weight:488.7

(2b,3a,5a,16b,17b)-2-(4-Morpholinyl)-16-(1-pyrrolidinyl)androstane-3,17-diol

119302-20-4
244 suppliers
$34.00/250mg

75-36-5 Synthesis

75-36-5
559 suppliers
$17.92/100G

(2b,3a,5a,16b,17b)-17-Acetoxy-3-hydroxy-2-(4-morpholinyl)-16-(1-pyrrolidinyl)androstane

119302-24-8
167 suppliers
$59.00/25mg

119302-22-6 Synthesis

Androstane-3,17-diol,2-(4-morpholinyl)-16-(1-pyrrolidinyl)

119302-22-6
14 suppliers
inquiry

Yield:119302-24-8 94.1 %Chromat. ，119302-22-6 2.1 %Chromat.

Reaction Conditions:

in dichloromethane at 23; for 24 h;Product distribution / selectivity;

Steps:

1
Acetyl chloride (23.0 ml, 0.3234 mole) was added to a solution of Compound II (107 grams, 0.2395 mole) in 2 liters of dichloromethane. The reaction mixture was set-aside for 24 hours at room temperature (about 23° C.). HPLC analysis of a reaction sample showed that the mixture contained 35.1% of Compound I, 0.3% of Compound II and 55.5% of Compound III. Aqueous HCl solution (10.5%, 305 ml) was added thereafter and the mixture was heated to reflux for 4 hours. After cooling to 2° C., the mixture was neutralized to pH 7.2 by adding 5 liters of 5% sodium bicarbonate solution, and the aqueous phase was removed. HPLC analysis of the organic phase showed a composition of 86.3% of the desired Compound I, 1.9% of Compound II and 8.8% of Compound III. The organic phase was washed with two portions of 500 ml of water, dried with Na₂SO₄and the dichloromethane was removed by evaporation. The residue was obtained as yellow crystals (98.4 grams, 84% yield). HPLC analysis of the residue showed it contained 94.1% of the desired Compound I, 1.6% of Compound II and 2.1% of Compound III.

References:

Adar, Eliezer;Sondack, David;Friedman, Oded;Manascu, Iosef;Fizitzki, Tamir;Freger, Boris;Arad, Oded;Weisman, Alexander;Kaspi, Joseph US2005/159398, 2005, A1 Location in patent:Page/Page column 8

119302-20-4
244 suppliers
$34.00/250mg